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Objective: Recently we reported the prevalence of thromboembolism in 
patients who underwent the Fontan procedure and its modifications. 
Although hemodynamic factors may well contribute to thromboembolism, 
recent evidence suggests that coagulation factor abnormalities may also 
play a role. We therefore set out to investigate the coagulation status in a 
group of patients who had undergone the Fontan procedure. Methods: The 
study population consists of 20 children who had undergone the Fontan 
procedure and its modifications. They were examined for coagulation factor 
abnormalities. Concentrations of serum albumin, total protein, and liver 
enzymes were also measured. The median age at the time of the operation 
was 6.2 years (17 months to 8 years) with a male/female ratio of 2.3:1. The 
median time from the Fontan repair was 4.9 years (18 to 76 months). 
Results: Protein C (p < 0.001), protein S (p < 0.02), and factor VII (p < 
0.001) were significantly lower than the normal range. The changes in 
serum albumin and total protein and factors II, IX, and X were not 
significant. Conclusions: It is possible that deficiency in protein C, protein S, 
and factor VII partly account for the prevalence of thromboembolism after 
Fontan-type repairs. The risk of long-term anticoagulation should be weighed 
against the best palliative procedure for these patients. We suggest that 
reduced protein C, protein S, and factor VII levels in this group of patients 
should be regarded as risk factors and that such patients should be treated 
with anticoagulants. (J Thorac Cardiovasc Surg 1997;113:989-93) 
T he Fontan operation was first reported in 1971 to provide correction of the circulation in patients 
with tricuspid atresia. 1Atriopulmonary or cavopul- 
monary anastomoses are now used as definitive 
palliation in a variety of complex congenital heart 
From the Department of Paediatric Cardiology and Cardiac 
Surgery a and the Thrombosis Research Institute, b Royal 
Brompton Hospital, London, United Kingdom. 
Read at the Seventy-sixth Annual Meeting of The American 
Association for Thoracic Surgery, San Diego, Calif., April 
28-May 1, 1996. 
Received for publication May 6, 1996; revisions requested June 
25, 1996; revisions received Feb. 17, 1997; accepted for 
publication Feb. 18, 1997. 
Address for reprints: Mr. C. Lincoln, Department of Cardiac 
Surgery, Royal Brompton Hospital, Sydney St., London SW3 
6NP, United Kingdom. 
Copyright © 1997 by Mosby-Year Book, Inc. 
0022-5223/97 $5.00 + 0 12/6/81252 
defects including double-inlet ventricle, pulmonary 
atresia with intact ventricular septum, and hypoplas- 
tic left heart syndrome. Common to all these con- 
ditions is that only one ventricle of adequate size or 
function is available to be useful. After the Fontan 
procedure or one of its modifications, the systemic 
venous return reaches the pulmonary circulation 
without being pumped by a ventricle. This highly 
abnormal circulation may be complicated by in- 
creased right atrial pressure, protein-losing enterop- 
athy with ascites, and thromboembolism. Thrombo- 
embolism is a widely recognized complication of the 
Fontan procedure and its modifications. Recently, 
we 2 reported the frequency of thromboembolism in 
64 patients who underwent a Fontan type of proce- 
dure between 1987 and 1992. Ten cases of throm- 
boembolic episodes were identified in the follow-up 
period, which ranged from 6 to 55 months. The 
episodes occurred 7 days to 4.5 years after the 
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Table I. Coagulation factor abnormalities in 20 patients who underwent the Fontan-type operation 
Below normal range Above normal range 
Normal range 
(%) No. p Value No. p Value 
Protein C 63-144 15 <0.001 0 0:6 
Protein S 66-144 4 0.02 0 0.6 
Antithrombin III 84-131 0 0.6 0 0.6 
Factor II 50-150 2 0.3 0 0.6 
Factor VII 57-165 11 <0.001 0 0.6 
Factor IX 50-150 1 1.0 0 0.6 
Factor X 50-150 2 0.3 0 0.6 
The normal range for all values represents he 90% confidence interval. 
Fontan repair. Seven of these were on the systemic 
venous or pulmonary aspect of the circulation, and 
three were on the systemic arterial aspect. In addi- 
tion, several other reports of thromboembol ism 
after the Fontan procedure have been published. 3-5 
Although hemodynamic factors including a low car- 
diac output and a less pulsatile pulmonary circula- 
tion than normal may contribute to thromboem- 
bolism, Cromme-Dijkhuis and colleagues 6 have 
evidence to suggest hat coagulation abnormalities 
may also play a role. We have therefore examined 
coagulation status in a group of patients who were in 
stable condition in the postoperative period. 
Patients and methods 
The study population includes 20 patients who were 
examined for coagulation factor abnormalities and liver 
function tests. The number of patients who have under- 
gone the Fontan procedure and its modifications in our 
institute is considerably larger. Some patients, however, were 
not able to attend follow-up or did not consent to participate 
in this study. In addition, in the case of patients receiving 
warfarin, it was considered inappropriate o stop and then 
recommence warfarin for the purpose of the study. For this 
reason, patients receiving warfarin were excluded from the 
study. In our institute all patients with a history of thrombo- 
embolic episodes receive warfarin unless contraindicated; 
therefore these patients were also excluded. 
All patients had undergone a Fontan-type operation. 
The median age at the time of the operation was 6.2 year 
(17 months to 8 years) with a male/female ratio of 2.3:1. 
The median time from the Fontan repair was 4.9 years (18 
to 76 months). Of the 20 patients, 11 had an anastomosis 
constructed between the right atrium and the pulmonary 
artery. A direct anastomosis was used in seven of these, in 
two patients a roof of polytetrafluoroethylene wasused, 
and in four a nonvalved pulmonary homograft was inter- 
posed between the right atrium and the pulmonary artery. 
Nine patients underwent total cavopulmonary connection, 
usually carried out by anastomosing the superior vena 
cava end to side to the right or left pulmonary artery and 
creating an intraatrial tunnel to conduct inferior vena 
caval blood to the superior vena caval orifice by means of 
a tunnel of polytetrafluoroethylene (  = 6) or pericar- 
dium (n = 3), with the right atrial free wall forming the 
posterior aspect. In five patients fenestration of the infe- 
rior caval baffle was performed with a 4 mm aortic punch. 
All patients were treated with aspirin and were asked to 
stop taking aspirin 1 week before the study. None of the 
patients were receiving diuretics or clinically had protein- 
losing enteropathy. Ethical committee approval was ob- 
tained and informed consent was given by all patients and 
their parents. Venous blood was obtained for coagulation 
studies. Protein C activity was measured by the chromo- 
genic substrate method of Behring Biochemical Company. 
Protein S antigen was measured by means of enzyme- 
linked immunosorbent assay. Factors II, VII, IX, and X 
were measured by means of a clotting assay, and anti- 
thrombin III was measured by means of a chromogenic 
assay. Levels of serum alkaline phosphatase, alanine 
transaminase, aspartate transaminase, total bilirubin, total 
protein, and albumin were measured with the use of an 
automatic linical analyzer. Concentrations of these pro- 
coagulant and anticoagulant factors were expressed as 
percentages of the concentration i  pooled normal plasma 
set at 100%. 
The normal range is 90% confidence interval for nor- 
mal samples. The p values are from a two-sided exact 
binomial test comparing the observed proportion of pa- 
tients above and below the normal range with the ex- 
pected proportion of 5%. 7 That is to test whether the 
observed proportion of patients with values below the 
normal range or above the normal range is significantly 
different from 5%. For total bilirubin, alkaline transami- 
nase, and aspartate transaminase concentrations, where 
the upper limit of the normal range is given, one would 
expect o see 10% of patients above the upper limit rather 
than 5%. Statistical analysis was performed with the use of 
the Stata statistical software package, version 5 (Claris- 
works, Apple; London, United Kingdom). 
Results 
The coagulation factor abnormalities are shown 
in Table I. Protein C, protein S, and factor VI I  
values are significantly lower than the normal range, 
whereas other values are not. The four patients with 
protein S deficiency all had reduced protein C levels. 
No significant difference in coagulation factor 
abnormalities was observed between those patients 
who had a right atr ial-pulmonary anastomosis and 
those who had a total cavopulmonary connection. 
Furthermore, no relation was seen between the 
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Table II. Liver function tests in 17 patients who underwent the Fontan-type of operation 
Below normal range 
Normal range 
(%) No. p Value 
Above normal range 
No. p Fb~e 
Total bilirubin <18 - -  - -  
Alkaline phosphatase 280-640 IU/L 2 0.2 
Alkaline transaminase <40 IU/L - -  - -  
Aspartate transaminase <50 IU/L - -  - -  
Total protein 62-82 gm/L 1 0.6 
Albumin 34-48 gm/L 2 0.2 
9 <0,001 
1 0.6 
1 1.0 
10 <0.001 
1 0.6 
0 1.0 
coagulation factor abnormalities, the type of heart 
defect, and the time of follow-up. 
The values for liver function tests are shown in 
Table II. The same method of analysis applied to the 
coagulation factors was applied to the liver function 
tests. Seventeen complete sets were obtained. The 
samples for three patients were mislaid. Concentra- 
tions of total bilirubin and aspartate transaminase 
were significantly elevated, and the total protein and 
serum albumin levels were within the normal range. 
Discussion 
Recently, we 2 reported a high frequency of 
thromboembolic complications after the Fontan 
procedure and its modifications. Unpublished ata 
reported in the World Congress of Paediatric Car- 
diology and Cardiac Surgery in 1993 indicated that 
the real frequency of thromboembolic complications 
may be even higher than reported owing to subclin- 
ical occurrence of pulmonary emboli. Having the 
Virchow's triad in mind, thromboembolism after the 
Fontan procedure could be due to stasis, the pres- 
ence of abnormal surfaces, and change in coagula- 
tion. The aim of the Fontan operation is to produce 
a circulation in which blood is transmitted from the 
right atrium to the pulmonary artery. In this highly 
abnormal circulation, where no ventricle is present 
to pump the blood, stasis and areas of sluggish flow 
can predispose to the formation of a venous throm- 
bus. Previously, we 2 showed no relation between the 
occurrence of thromboembolism and the use of 
foreign material, although the numbers were not 
large. The fact that thromboembolic episodes occur 
both on the pulmonary venous and on the systemic 
arterial aspect of the circulation led us to believe 
that a coagulation disorder may partly be responsi- 
ble for thromboembolism after the Fontan procedure. 
Protein C is a natural anticoagulant synthesized in
the liver as a vitamin K-dependent protein, s After 
activation by thrombin, protein C is a potent inhibitor 
of the coagulation cascade and stimulates fibrinolysis. 
Protein S acts as a cofactor in this pathway, and it 
further stimulates fibrinolysis. 9 Protein C deficiency 
with or without protein S deficiency, either inherited 
or acquired, has been associated with increased throm- 
botic activity, m' 11 In this report we have demonstrated 
a significant decrease in protein C and protein S 
concentrations after the Fontan repair. This confirms 
the findings of Cromme-Dijkhuis and colleagues, 6 who 
reported protein C deficiency as the most common 
and most pronounced abnormality inpatients who had 
undergone the Fontan operation. In a similar study, 
they j2 reported normalization of protein C levels in 
patients who underwent the Fontan operation. The 
significance of this finding remains to be explained. In 
the present study we failed to show aw recovery of the 
protein deficiencies. 
Factor VII is a coagulation factor and is part of the 
extrinsic pathway. Factor VII interacting with tissue 
factor activates the extrinsic mechanism. In this study, 
we showed a deficiency of factor VII in 55% of the 
patients, which theoretically should predispose to 
bleeding and not coagulation. However, experimental 
evidence suggests that very low concentrations of
factor VII activity can support issue factor-induced 
coagulation in pathologic states. 13 Furthermore, the 
risk for thromboembolism is apparently increased in 
patients with hereditary factor VII deficiencyJ 4 
Abnormalities of liver function tests in patients 
who have had the Fontan operation have previously 
been reported. Is In this report, concentrations of
aspartate transaminase and total bilirubin were 
raised. However, no clinical evidence of hepatic 
dysfunction was observed. Total protein and serum 
albumin concentrations were not significantly re- 
duced. We showed no correlation between liver 
function tests and coagulation abnormalities. This 
suggests that the overall synthesizing function of the 
liver in this group of patients was normal. It is 
difficult o explain the deficiency of protein C, but it 
may be due to a selective defect in liver synthesis. 
The deficiency in protein C may partly account for 
the occurrence of thromboembolism after the Fortran 
procedure. One practical implication of this finding is 
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that long-term anticoagulation should be administered 
after the operation. However, the risks of long-term 
anticoagulation, especially in children, should be 
weighed against the benefits of the best palliative 
operation available for their complex congenital heart 
disease. We suggest hat a postoperative decrease in 
protein C and protein S concentrations should be 
regarded as risk factors, and patients deficient in these 
proteins hould be administered anticoagulants selec- 
tively. 
We thank Mrs. Caroline Dore for statistical advice. 
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Discuss ion 
Dr. Richard A. Jonas (Boston, Mass.). The invited 
discussant for this paper was my colleague, Dr. John 
Mayer. who had to return to Boston. He passed on to me 
some of his thoughts and questions. 
We have long been concerned abom the problem of 
thromboembolic stroke after the Fontan procedure, We 
have encountered this complication ourselves in Boston 
and have reported on this problem in a paper published. 
I believe, in theAnnaIs of Neurology. We applaud you for 
addressing what we consider to be an important topic. I 
hope you will help us to pinpoint exactly what the 
predisposing factors might be in this problem. 
Dr. Mayer's questions are as follows: First, have you 
made any attempt to correlate the changes in coagulation 
factors with either early or late hemodynamics, particu- 
larly right atrial pressure, duration of chest ube drainage, 
or length of hospital stay? 
Second. have you seen any correlation with the tech- 
nique of operation or the type of material used in the 
partition between the pulmonary and systemic venous 
return? In Boston we seemed to have an epidemic of 
systemic thromboemboli 3 or 4 years ago. When we 
changed from the tubular graft polytetrafluoroethylene, 
which had an external wrap, to the polytetrafluoroethyl- 
ene patch material, this problem seemed to decrease in 
frequency. 
Third. you recommended that patients with a low 
protein C or protein S concentration should receive 
anticoagulants. Inasmuch as protein C is dependent on 
vitamin K. what do you measure to ensure that you 
have tipped the balance of prothrombotic versus anti- 
thrombotic systems in the direction of opposing throm- 
bosis? 
Miss Jahangiri, Thank you very much for your com- 
ments and your questions, Dr. Jonas. Unfortunately, I do 
not have data on the coagulation factors and hemody- 
namic variables, and we have not attempted to correlate 
them. but that is a very good idea. 
The length of hospital stay was not significantly differ- 
em from that of the other patients having the Fontan 
procedure. However. the patients with thromboembolic 
episodes were not included in this study. 
As for the correlation with the techniques and the type 
of material, none of these patients had a history of 
thromboembolism. The only correlation we found was in 
the previous study, in which 10 of 64 patients were 
identified with thromboembolic episodes. Patients who 
had a fenestration and residual fenestration i the fol- 
low-up period seemed to be at increased risk. 
We monitor adequate anticoagulation by measuring the 
international normalized ratio. 
Dr. Leonard L. Bailey iLoma Linda. Calif.). The one 
thing that seems missing from your report is any sort of a 
control set. Did you consider assessing for these proteins 
before the Fontan operation in the same group of pa- 
tients, so that they could be their own controls, or could 
you select another set of controls to examine these 
proteins and to see whether it is unique to children having 
the Fontan procedure? 
Miss Jahangiri. Preoperative samples were not taken. 
The controls were obtained from a collection of pooled 
plasma from age-matched patients. However, this is an 
ongoing study, and we are currently measunng the pre- 
operative and postoperative coagulation status of our 
patients. 
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Dr. Bailey. if I were to do a routine ventricular septal 
defect operation today and measure these proteins during 
the coming week or so, would I expect o see any sort of 
abnormality? 
Miss Jahangiri. You shouldn't. The only study I am 
aware of in which a preoperative assessment was made 
of the coagulation status of patients with congenital 
heart disease of various types is a study by Dr. Turner- 
Gomes and Dr. Williams from Toronto. They evaluated 
thrombin regulation and showed that the levels were 
basically normal; and some of those children were 
cyanotic. 
Dr. Bailey. I look forward to continued feedback from 
your investigations. 
Notice of correction 
In the March 1997 issue of the Journal, in the article by Sawant and associates titled "St. Jude 
Medical Cardiac Valves in Small Aortic Roots: Follow-up to Sixteen Years" (1997;113:499-509), 
an incorrect copy of Fig. 1 was published. The correct copy of Fig. 1 is reproduced below. 
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Fig. 1. Preoperative and follow-up NYHA functional class presentation. Pts~ Patients. 
